|
|
|
Suture
|
Cath Lab Digest contains unique articles and information on the topic of suture based vessel closure. Feel free to browse through our articles below. |
|
Physicians Are Turning to RT(R)s to Achieve Immediate Hemostasis in the Cardiac Cath Lab
A Perclose Suture-Mediated Closure Program
|
A Successful Suture-Mediated Closure Program: Turning Your Lab Into a Profitable Entity
A Successful Suture-Mediated Closure Program: Turning Your Lab Into a Profitable Entity Feature: A Successful Suture-Mediated Closure Program: Turning Your Lab Into a Profitable Entity - Donna Florio-Bronen, RN, ANCC, Anthony Pucillo, MD, Westchester Medical Center, Valhalla, New York Purpose: To describe how the cardiac catheterization lab at Westchester Medical Center increased hospital revenues as a result of changing its groin management protocol. In addition to increased procedural ...
|
June 2004
Next Generation Suture-Mediated Vessel Closure System Abbott Vascular Devices, a division of Abbott Laboratories, announced the launch of the next generation Perclose® suture-mediated vessel closure system, Perclose ProGlide? Microsurgical Dilatation Device Boston Scientific Corp. announced the results from the Cutting EDGE clinical trial for its Peripheral Cutting Balloon Device. Mr. Sheridan founded or helped found four major medical catheter companies: United States Catheter and ...
|
Advances in Coronary Intervention: Focus on Subacute Stent Thrombosis PhosphorylCholine (PC) Coated Stents and Suture-Mediated Closure Synergy
Balloon angioplasty results in enlargement of the vessel lumen by creating a controlled dissection at the site of atherosclerotic stenosis. Post angioplasty result is an irregular vessel lumen (due to extensive dissections in the intima and the media), accompanied by significant elastic recoil1-3. Both of these factors predispose to acute or subacute thrombotic occlusion at the site of angioplasty. Stent-supported angioplasty allows effective luminal scaffolding, creating a uniformly larger lumen and allowing larger ?acute gain? by eliminating elastic recoil. The evolution of stent technology has brought forward a certain level of clinical improvement with regards to subacute thrombosis4 and long-term restenosis5,6. Even with great clinical advances and design enhancements, the fact remains that so long as we continue to implant bare metal stents, we are exposing patients to thrombogenic material that is not biocompatible. Albeit low, this poses a finite risk to patients with associated catastrophic clinical sequale. The risk of subacute thrombosis is particularly higher in certain subsets of patients (acute coronary syndromes, emergently placed stents, lesions treated using multiple stents, hypercoagulable states, angiographically visible thrombus, long calcified lesions in smaller vessels and patients with history of cocaine abuse)7-11.
|
Research Update: Original Research Abstracts from The Journal of Invasive Cardiology
Selected abstracts from June 2006 ? September 2006.
|
Symmetry?! Bypass System Aortic Connector: A Star is Born!
The connector can be visualized under fluoroscopy, since it is made of the same material as intracoronary stents. It serves as its own location marker during coronary angiography, which makes the search for grafts substantially less tedious.
|
Vascular Access Site Hemostasis: "An Endovascular Surgeon's Perspective" Manual Compression May Not Be Benign Part 1
I am a classically trained cardiac and vascular surgeon and a member of the Cardiovascular Institute of the South, a group in which equal clinical and equitable partnerships have been formed between cardiologists and surgeons. This group actually encompasses approximately 45 cardiologists and 9 cardiovascular surgeons who work intimately together, so I learned long ago to respect the cath lab.
|
In Brief: Original Research Abstracts from the Journal of Invasive Cardiology
The following abstracts are reprinted with permission from the December 2002, January 2002 and February 2003 issues of the Journal of Invasive Cardiology.
|
Angiolink's Staple-Mediated VCD Addresses Limitations of Current Technology Part II
Our vascular closure devices today have significant limitations (Table 1). What we really need to do is to develop an ?ideal? vascular closure device (VCD). Thankfully, there are new technologies coming out that hopefully are addressing this issue. Figure 1 is a novel device called the Angiolink EVS? staple device. It is not yet FDA-approved, but Angiolink has just finished doing a pivotal trial and anticipate approval in the fall of 2004. We have worked on this project with Angiolink (Tauton, Massachusetts) for 4 years.
|
Device Update I: The Angio-Seal? Device: A Current State Assessment of Changing Clinical Practice
About Angio-Seal The Angio-Seal STS and STS Plus allow closure to be completed on the cath lab table. Following the removal of the procedural sheath, Angio-Seal achieves hemostasis at the femoral arteriotomy without the aid of external pressure to the groin. In January 2002, the Angio-Seal STS Platform was introduced in the United States.
|
|
|
|
|
|
|
|
On Demand Medical Education
|
|
|
|
|
